VRCA
HEALTHCAREVerrica Pharmaceuticals Inc
$8.43+1.27 (+17.74%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VRCA Today?
No stock-specific AI insight has been generated for VRCA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.28$9.82
$8.43
Fundamentals
Market Cap$145M
P/E Ratio—
EPS$-1.68
Dividend Yield—
Dividend / Share—
ROE-2.4%
Profit Margin-0.5%
Debt / Equity—
Trading
Volume475K
Avg Volume (10D)—
Shares Outstanding17.2M
VRCA News
20 articles- Lipocine (LPCN) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDAYahoo Finance·May 6, 2026
- Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue EstimatesYahoo Finance·May 5, 2026
- Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual MeetingYahoo Finance·May 5, 2026
- Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026Yahoo Finance·May 5, 2026
- Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingYahoo Finance·Apr 9, 2026
- Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 6, 2026
- Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...Yahoo Finance·Mar 11, 2026
- Verrica Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 11, 2026
- Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 11, 2026
- Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026Yahoo Finance·Mar 5, 2026
- Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 23, 2026
- Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial OfficerYahoo Finance·Feb 12, 2026
- Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii PharmaceuticalYahoo Finance·Feb 9, 2026
- Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's WhyYahoo Finance·Feb 2, 2026
- New Strong Buy Stocks for February 2ndYahoo Finance·Feb 2, 2026
- How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%Yahoo Finance·Jan 12, 2026
- Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common WartsYahoo Finance·Jan 7, 2026
- Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash RunwayYahoo Finance·Nov 24, 2025
- Verrica Pharmaceuticals Inc (VRCA) Q3 2025 Earnings Call Highlights: Revenue Surge and ...Yahoo Finance·Nov 17, 2025
All 20 articles loaded
Price Data
Open$6.43
Previous Close$7.16
Day High$7.20
Day Low$6.38
52 Week High$9.82
52 Week Low$3.28
52-Week Range
$3.28$9.82
$8.43
Fundamentals
Market Cap$145M
P/E Ratio—
EPS$-1.68
Dividend Yield—
Dividend / Share—
ROE-2.4%
Profit Margin-0.5%
Debt / Equity—
Trading
Volume475K
Avg Volume (10D)—
Shares Outstanding17.2M
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatological therapy company, develops and markets treatments for people with skin conditions in the United States. The company is headquartered in West Chester, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—